peptidesciences retatrutide for Weight Loss: TRIUMPH-1 Results, Cost, Insurance Retatrutide | Triple Agonist Research

But GLP-1 medications are not part of the usual trend cycle

In the UCLA RA study, GI side effects were the top reason patients discontinued

Proper handling, using sterile needles, and limiting unnecessary opening of the vial can help reduce this risk

If an unopened pen has been left at room temperature, check your specific product's patient information leaflet for allowable time periods outside refrigerationsome products like Trulicity permit up to 14 days at temperatures up to 30C before first use

Phase 3 TRIUMPH-1 Results (Reported 21 May 2026) On 21 May 2026, Eli Lilly reported topline results from TRIUMPH-1 , the pivotal Phase 3 obesity trial, the first Phase 3 efficacy readout in the retatrutide programme

Research Peptides Peptide compounds sold for research purposes that exist in a regulatory gray area